Hedge funder’s first assault on iffy drug patents? Acorda’s MS med Ampyra

Tracy Staton

Last month, Texas fund manager Kyle Bass said he had pharma and its "questionable" in his sights. Now, he's made his move–and he's said 14 more targets will follow.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS